Author Archives: Brian Klepper

About Brian Klepper

Brian Klepper is a health care analyst, commentator and a Principal in Health Value Direct.

Why U.S. Prescription Drugs Prices are the Highest in the World

By Patricia Salber MD, MBA August 24, 2016 Originally Posted on The Doctor Weighs In on 8/24/16 It was hard to contain my outrage as I made my way through a special communication in the August 22/23, 2016 JAMA written … Continue reading

Rate this:

Posted in General | Leave a comment

Employers, Unions Look to Direct Contracting

Brian Klepper and Fred Goldstein Published 8/17/16 in Employee Benefit News Industry denials notwithstanding, reducing healthcare costs is fundamentally against nearly every healthcare organization’s perceived economic interests. That’s why it’s been such a struggle for purchasers to find healthcare organizations that … Continue reading

Rate this:

Posted in General | Leave a comment

The Gold Standard for Current Cancer Treatment

This gallery contains 2 photos.

Published Online 6/27/2016 in JAMA Internal Medicine. A couple of months before Elaine died from peritoneal cancer, we hired Anila, a cheerful, hearty Albanian house cleaner. On her first visit, Anila saw that Elaine was bedridden. “Kerosene can save her,” … Continue reading

Rate this:

| 3 Comments

Patients and Physicians Should Share Decisions in Oncology

Posted 8/2/16 on the CollabRx Blog Q: Many of us have been touched by the publication of your sensitive but serious criticism of your wife’s care once her ultimately lethal peritoneal cancer had spread. How do you propose that oncologists, … Continue reading

Rate this:

Posted in General | 1 Comment

When Its More Profitable To Raise Rates Than Manage Care

Brian Klepper & Fred Goldstein Posted 5/24/16 on The Doctor Weighs In A recent Associated Press story reported that two health plans with deep managed Medicaid experience, Molina and Centene, have been successful with their commercial exchange offerings. The experience … Continue reading

Rate this:

Posted in General | 1 Comment

The Emergence of High Performance Health Care

By BRIAN KLEPPER Posted 4/7/2016 on The Health Care Blog The health care mainstream is investing in a variety of mechanisms to beat back America’s health care cost and quality crisis –  ACOs, medical homes, data analytics, practice transformation, technology … Continue reading

Rate this:

Posted in General | 1 Comment

13 Questions To Ask Onsite Clinic Vendors

Brian Klepper Published 2/24/10 in Workforce Magazine Thinking about opening a primary care clinic at your business site? Many organizations are. Work-site medical clinics are catching on as employers discover they can save significant dollars and improve the care for … Continue reading

Rate this:

Posted in Brian Klepper, Clinics, Conflicts of Interest, General, Health Care Cost | Leave a comment

Why High Performance Health Care Remains Elusive

By Brian Klepper Published 3/31/16 in Employee Benefits Advisor Do you know about a high-value healthcare program that wildly exceeded your expectations by delivering provably better health outcomes at dramatically lower cost? If so, I want to know about it. High … Continue reading

Rate this:

Posted in General | 1 Comment

Congress’ Drug Addiction

Posted 2/26/16 on Employee Benefit News. The Congressional committee that recently demanded Martin Shkreli’s appearance must have hoped to spotlight a smug jerk responsible for the outrageous prescription drug pricing that we’re all up against. Of course there are lots of … Continue reading

Rate this:

Posted in Benefits, Brian Klepper, Conflicts of Interest, Health Care Cost, Market Dynamics, Medical Management, Policy/Law/Regulation, Politics, Quality | Tagged , , , , | 9 Comments

Florida’s Governor Scott and the Public’s Trust

Brian Klepper Originally Posted 1/17/16 on The Doctor Weighs In A CNN investigation by Elizabeth Cohen and Katherine Grise asserts that Florida Governor Rick Scott’s administration has scuttled longstanding state hospital quality standards after two Republican political groups received large contributions … Continue reading

Rate this:

Posted in General | Leave a comment

Why Does The FDA Approve Cancer Drugs That Don’t Work

BRIAN KLEPPER Posted 10/23/15 on The Health Care Blog A new study in JAMA Internal Medicine finds that two-thirds of cancer drugs considered by the US Food and Drug Administration (FDA) over the past five years were approved without evidence that … Continue reading

Rate this:

Posted in Analytics, Brian Klepper, Conflicts of Interest, Health Care Cost, Innovation, Life Sciences, Market Dynamics, Policy/Law/Regulation | Tagged , , | 3 Comments

Is Oncology Ground Zero For Reform?

…cancer professionals – physicians, researchers and society execs – have felt uncomfortably complicit with a paradigm that too often extracts exorbitant sums of money for miniscule clinical benefit. Continue reading

Rate this:

Posted in General | Tagged , , | 2 Comments

The Goose and the Elephant

…striving for ever-higher earnings, drug companies large and small are relentlessly increasing pricing on old and new drugs because they can. They can because the industry successfully deployed lobbyists who persuaded a receptive Congress to heavily favor their interests, spinning laws away from regulatory controls and toward payment at any price. These circumstances, nurtured by pharma itself, make a 55-fold price increase possible and legal, if outrageous. And that’s the elephant in the room. Continue reading

Rate this:

Posted in General | Tagged , , , , , , | Leave a comment

The Case for High Performance Health Care

Brian Klepper Posted 9/25/15 on The Employee Benefit News Blog Note to would-be health care reformers: don’t bother trying to drive change through policy, because you’re vastly outgunned. The industry you would reform owns Congress and the legislatures. Nearly every … Continue reading

Rate this:

Posted in General | Leave a comment

Will Specialty Drug Pricing Be The Straw?

Published 5/27/15 in Employee Benefit News Over the next few years, drug manufacturers will release a host of new drugs that are more complex and, in many cases, more effective than we’ve had access to in the past. There will be … Continue reading

Rate this:

Posted in Analytics, Benefits, Brian Klepper, Health Care Cost, Innovation, Life Sciences, Market Dynamics, Medical Management, Policy/Law/Regulation, Politics, Quality | Tagged , , | Leave a comment